logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
5/26/2020 8:03:46 AM Kala Pharma Announces FDA Acceptance Of NDA For EYSUVIS(tm) For Dry Eye Disease
5/4/2020 8:09:42 AM Kala Pharmaceuticals Resubmits NDA For EYSUVIS For Dry Eye Disease
4/17/2020 4:10:41 PM Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3/10/2020 11:07:11 PM Kala Pharmaceuticals Announces Pricing Of Public Offering Of 16 Mln Shares At $7.89/shr
3/9/2020 6:05:04 AM Kala Pharma Announces Positive Topline Results From STRIDE 3
2/12/2020 7:26:35 AM Kala Pharmaceuticals Q4 Loss Per Share $0.63 Vs Loss $0.76 Last Year
11/7/2019 7:24:41 AM Kala Pharmaceuticals Q3 Net Loss $23.2 Mln Or $0.68 Per Share
8/7/2019 8:52:04 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY20 Rev. Estimate To 35.1 M From 54.7 M
8/7/2019 8:51:51 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q4 20 Rev. Estimate To 12.5 M From 28.0 M
8/7/2019 8:51:39 AM Wedbush Is Lowering Kala Pharmaceuticals, Inc. (KALA) Q3 20 Rev. Estimate To 9.7 M From 13.8 M
8/7/2019 8:51:21 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY19 Rev. Estimate To 10.9 M From 11.2 M
8/7/2019 8:50:55 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY20 Estimate To -2.64 From -2.40
8/7/2019 8:50:43 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q4 20 Estimate To -0.61 From -0.28
8/7/2019 8:50:30 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q3 20 Estimate To -0.68 From -0.65
8/7/2019 8:50:19 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q2 20 Estimate To -0.68 From -0.75